CRDF (Cardiff Oncology Corp) נכסי מאזן של החברה

This chart of total assets for Cardiff Oncology, Inc. (CRDF), valued at 56.58, illustrates the business's financial standing. Cardiff Oncology, Inc. (CRDF) relies on US-based R&D centers developing advanced inhibitors to enhance chemotherapy for colorectal and prostate cancers. The strategy is based on the implementation of Onvansertib with biomarkers to establish long-term treatment protocols; however, the lack of commercial products leaves the capitalization dependent on external financing during Phase II trials.

The resilience of Cardiff Oncology, Inc. (CRDF) to market shocks depends directly on the funding efficiency for the development of its colorectal cancer therapy inhibitor. Successful completion of clinical phases and partner support minimize liquidity risks. This calculation of total assets, derived reverse-engineered through ROA, reflects the aggregate value of all business resources and liabilities. Investors should interpret the indicator's trend as a consensus valuation of the company's fundamental base.